Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis

BACKGROUND: BRAF inhibitor and dual BRAF/MEK inhibitors have been approved for the treatment of BRAF-mutated melanoma. Cutaneous squamous cell carcinoma (cuSCC) is an adverse event associated with these drugs. The contribution of BRAF inhibitor and dual BRAF/MEK inhibitors to cuSCC are still unknown...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Ling, Wang, Yina, Hong, Yun, Ye, Xianghua, Shi, Peng, Zhang, Junyan, Zhao, Qiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669968/
https://www.ncbi.nlm.nih.gov/pubmed/29137342
http://dx.doi.org/10.18632/oncotarget.21059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669968/
https://www.ncbi.nlm.nih.gov/pubmed/29137342
http://dx.doi.org/10.18632/oncotarget.21059

Ejemplares similares